Biosceptre has outstanding commercial, financial and scientific capabilities. The Management Team is comprised of:
Board of Directors
Peter Newton Non-Executive Chairman
Peter has an extensive financial background having spent 26 years as a stockbroker. Peter is a former CEO of County Natwest. He is currently the Chairman of Metals X Ltd. and a director of two other Australian-based companies. He has enjoyed success in guiding investment and growth, and has substantial experience in corporate governance issues.
Gavin Currie Chief Executive Officer
Gavin was appointed CEO of Biosceptre International Ltd in October 2012, having been a Board member since 2009. Prior to taking the CEO role at Biosceptre, Gavin was General Manager of Creata Ventures, a family-held investment fund with a strong biotech focus. Biosceptre was a key investment within that fund.
Gavin previously founded a boutique transaction services company and has significant experience in M&A, particularly integrating businesses post transaction. Gavin has developed a reputation for delivering value by commercialising previously unseen opportunities and has been employed internationally in Australia, New Zealand, England, USA and Hong Kong, with experience in cross-border transactions and investments.
Michael Lovett Non-Executive Director
Michael is Chairman of MobiLife Pty Ltd – a drug compounding company; owner of Bioption Investments (HK) Ltd – a private investment fund; owner of Ambrosia Trading (Shanghai) Ltd – a manufacturing business; Non Executive Director of KaosKey Pty Ltd – a medical device company; and a Non Executive Director of Dr’s Beck & Stone – a China based veterinary hospital group.
Michael is a qualified psychologist, he founded and was the CEO of one of the UK’s largest social care businesses which after growing organically and through acquisitions he sold to Private Equity. After moving to Hong Kong Michael expanded his entrepreneurial interests by setting up a private investment vehicle through which he invests predominantly in the medical sciences and medical device sector.
Michael is a Fellow of the Royal Society of Arts and of the Institute of Directors.
Dr Ron Watts, PhD Non-Executive Director
Ron has worked at senior levels in government and at CEO and Board level across a range of technology-based enterprises.
His management experience covers software and telecommunications industries, and as a consultant he has worked with companies on strategy and fund-raising in biotechnology, utilities, food processing and energy. He co-founded Australia’s largest energy market intermediary, Energy Action and is its chairman.
Ron has served on a number of government and industry oversight bodies, and as Adjunct Research Fellow at UniSA. He has a Bachelor of Science (Honours) from the University of New South Wales and a PhD from Cambridge University.
Andrew Walton-Green Non Executive Director
Andrew joined Biosceptre in December 2014. He is a Chartered Accountant and a member of the Chartered Institute of Taxation. Most recently, Andrew was a founder and CEO of The Car Finance Company, one of the fastest growing companies in Europe over the past 4 years. He is also a part owner of a renewable energy business in the UK, a technology distribution company and a fast growing wholesale pharmaceutical business.
Before this he was the CEO of Gresham Computing plc for 10 years, gaining significant exposure to the banking and financial services sector at a senior level. Andrew spent the first 13 years of his career in practise predominately with Ernst & Young and then Deloitte.
Jon Collins Non Executive Director
Jon joined the board of Biosceptre in December 2014. Jon is the owner and Chairman of The Coco Group, an investment and business expansion consultancy based in Australia, with global connections. Jon moved to Australia in 1987, to rebuild an existing group of businesses for which he led a successful management buy-out from the UK owners in 1993, and became the sole owner in 1997. This business developed into a major manufacturer of specialised pumping equipment with offices in the USA, Indonesia, UK, Middle East and South Africa. The company was sold to an ASX-listed company in November 2010. Jon started his industrials career in 1967, in capital equipment sales and equipment rental, taking posts in the USA and Ireland, and rose through the ranks from junior management to a directorship.
With a keen interest in rugby, Jon has also served as a director of the New South Wales Waratahs (Super 15) and the Australian Rugby Union.
Paul Axon Non Executive Director (Alternate to Jon Collins)
Paul Axon is a qualified Pharmacist and a Chartered Accountant in the UK and Australia, having vast experience in mergers and acquisitions, corporate finance and general management. Previously, Paul was a partner in corporate finance at BDO in the UK and had owned his own mergers and acquisitions practice. More recently, Paul was the CEO of Sykes Pumps, until the sale of the business to National Hire in 2010.
Currently, Paul is the CEO and equity holder of the Coco Group, who invests in and manages a vast array of businesses in Australia and the Middle East, including interests in equipment rental, mining services, retail, biotechnology and resources.
Dr Shaun McNulty, PhD, Chief Scientific Officer
Shaun joined Biosceptre in January 2014. With over 20 years of experience working in the Pharmaceutical and Biotechnology sectors across a range of functions from target identification, drug discovery and portfolio management to product and commercial development. Shaun is experienced in strategic planning, drug discovery and product development and brings broad industry understanding to the scientific and commercial sides of the business.
Having obtained his doctorate from the University of York, Shaun undertook 5 years of post-doctoral study at the University of Cambridge. He then held positions at GSK, Pfizer and Syntaxin, managing a number of scientific teams, international drug discovery projects and drug development portfolios. Shaun joined ImmBio in 2008, establishing scientific links and the commercial strategy that led to the company obtaining multiple grants to develop its vaccine products. Currently, Shaun directs Biosceptre International’s portfolio of drugs through research and clinical development stages.
Dr Julian Barden, PhD Director of Research
Julian is a protein structure specialist. He has over 30 years experience working on protein structure analyses, molecular modelling, protein function studies and antibody design in several areas. These include the molecular mechanism of muscle contraction, actin structure and function, calcium regulating hormones, purinergic receptor structure and function and the development of cancer diagnostics and lead cancer immunotherapeutic molecules. Julian has authored 150 international papers, sixteen patent families and has presented over 200 papers at national and international scientific meetings.
Dr David Chin, PhD Director of Bioproduction and Research Collaboration
David has worked in biopharmaceuticals for nearly 20 years with significant experience in recombinant protein expression, in both microbial and mammalian cell systems, and monoclonal antibody discovery and engineering. On completion of his PhD at the University of New South Wales, Australia, he was awarded a research fellowship by the Australian Research Council (ARC) through which he researched various biopharmaceuticals in the fields of oncology and inflammation. With further training in business administration, David has taken up several senior and managing positions.
Prior to joining Biosceptre David was operation manager at National Biologics Facility (NBF) at the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, in the area of recombinant protein production, cell line generation and protein characterisation. In this post David managed over 20 scientific staff controlling a budget of over $A30 million, established over 30 collaborations between the biotech industry and academia and accomplished over 300 commercial and research projects at AIBN. David was also appointed as Chief Operating Officer at Stem Cell Limited, a spin-off from University of Queensland and Monash University.
Michael Ashby CIO and Commercial Manager
Michael joined Biosceptre in late 2012 to ensure that both the Information Systems and Operational Structures will support the strategic and commercial initiatives of the Company. Michael has over 20 years experience working at senior management levels in a variety of organisational sectors, including healthcare, Information Technology, FMCG and education. Michael holds an MBA, from the Macquarie Graduate School of Management, Australia, and post graduate diplomas in Education and Information Technology.
Brad Miller Senior Manager – Legal & Compliance
Brad joined Biosceptre as Senior Manager – Legal & Compliance in May 2013 after five years with a private international investment fund. With practical knowledge in both financial management and legal documentation, Brad gained hands on experience across a broad range of cross-border transactions including mergers and acquisitions, debt financing and equity investments, primarily in the life sciences sector. Brad holds a Masters of Business Law from the University of Sydney and a Bachelor of Business Administration from Macquarie University.
Scientific Advisory Board
Dr Sir Gregory Winter, CBE, FRS, FMedSci, HonFRCP
Gregory is a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge, and a Fellow of Trinity College Cambridge. He has served LMB as a Head of Division, Deputy Director and Acting Director. His scientific career has almost entirely been based in Cambridge where his work included protein sequencing (aminoacyl tRNA synthetases) and nucleic acid sequencing (influenze virus). He later developed technologies for making humanised antibodies (by grafting hypervariable regions from rodent antibodies to human antibodies) and also for making human antibodies in bacteria (by use of antibody repertories and phage display technologies). Most of the therapeutic antibodies on the market were developed using methods devised by him. He was a Founder and Director of Cambridge Antibody Technology (acquired by AstraZeneca), a Founder and Director of Domantis (acquired by GSK) and more recently a Founder and Director of Bicycle Therapeutics. Sir Gregory has received numerous international prizes and awards, and in 2004 was knighted for services to Molecular Biology.
Professor Terence Rabbitts FRS, FMedSci
Terence worked in Cambridge from 1973-2006 in the MRC Laboratory of Molecular Biology where he was head of the Division of Protein & Nucleic Acid Chemistry until 2002. He moved to become Director of the Leeds Institute of Molecular Medicine (from 2006 to 2010). He is a Member of the European Molecular Biology Organization (EMBO); a Fellow of the Royal Society (FRS); and a Founder Fellow of the Academy of Medical Sciences (FMedSci).
His scientific work includes pioneering the method of cDNA cloning, mapping human antibody genes, methods for chimaeric antibody production and single domains for blocking protein interactions inside cells. He defined the linkage of antibody and T cell receptor genes with cancer-specific chromosomal translocations, identified new families of oncogenes (such as the LMO2 and HOX11 families) and identified a first gene fusion in a solid tumor (FUS-CHOP). He developed the first gene fusion knock-in and also methods for creating chromosomal translocations de novo.
He has considerable corporate biotechnology experience as chairman of the SAB of Cambridge Antibody Technology and Quadrant Healthcare until their respective IPOs; and a member the Domantis SAB until the company’s acquisition by GSK. He is currently Chairman of the SAB of Kymab and is a member of the SAB of Oryzon Genomics and of DiThera.